Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic PBSCT with Fludarabine/Cyclophosphamide in High Risk CLL
NCT00002838Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 1995
- Primary completion
- Jul 2002
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, cyclophosphamide in chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 1995; status: completed.
02
Drugs
fludarabinecyclophosphamide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00002838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002838.